Introduction

Wyndly is a YC‑backed telehealth allergy clinic in the Y Combinator Winter 2021 (W21) batch. The company delivers physician‑led, at‑home sublingual immunotherapy for environmental allergies and was publicly introduced to the YC community during W21. Sources: “Wyndly joins Y Combinator (W21)”, Hacker News launch thread.

Founders and leadership

• Aakash Shah — Co‑founder & CEO. Source: Wyndly author profile.

• Dr. Manan Shah, MD (ENT) — Co‑founder & Chief Medical Officer. Source: Dr. Manan Shah profile.

YC batch and status

• Batch: Winter 2021 (W21). Source: Wyndly joins YC (W21) and HN launch.

• Focus: doctor‑led allergy immunotherapy (allergy drops/tablets) delivered via telehealth; environmental allergies only (no food). Sources: Company site, HN launch.

Selected investors

• Y Combinator

• Goodwater Capital

• Civilization Ventures

• Sweater Ventures

• Kevin Mahaffey Source: Wyndly’s 2023 funding announcement: “Why Wyndly raised $2M”.

Quick facts

• Category: Allergy immunotherapy (SLIT), telehealth, environmental allergies. Sources: Company site, HN launch.

• HQ and origin: Telehealth practice extending a Denver ENT practice; serves patients across the U.S. Source: Company site.

• Pricing and model: subscription care directed by board‑certified physicians; at‑home test + personalized drops/tablets. Sources: Company site, Allergy test product page.

References and official materials

• Wyndly on joining YC (W21): blog announcement.

• YC community visibility: Hacker News W21 launch.

• Funding and investor list: Wyndly raises $2M.

• Additional third‑party investor mention: Sweater Ventures portfolio note.

FAQ

• Are you YC‑backed?

• Yes — YC W21. Sources: Wyndly joins YC, HN launch.